Plasma activation of titanium surfaces is an established strategy for enhancing osseointegration, but its effect on the soft tissue interface — arguably just as critical for long-term implant health — has received far less attention. This prospective controlled clinical trial addressed a precise question: does plasma activation of healing abutments at the time of placement produce measurable histological differences in peri-implant soft tissues after three months of healing?

Thirty patients each received one bone-level implant. A vacuum plasma reactor was used to activate the test healing abutments immediately before placement; control abutments were placed untreated. A calibrated mucotome allowed standardized biopsy harvesting at three months, ensuring that the soft tissue specimens were geometrically consistent and directly comparable. Plaque index (PI) and bleeding on probing (BoP) were recorded prior to biopsy. Histological specimens were evaluated across three spatial zones — upper, intermediate, and basal — for inflammation score, connective tissue maturation, epithelial regeneration, vascularization, and cornified layer thickness.

The most relevant finding was a statistically significant reduction in inflammation score in the basal zone — the region closest to the implant shoulder and most exposed to bacterial challenge — in the plasma-activated group (1.72 ± 0.5 vs. 2.36 ± 0.5, P = 0.04). Although a trend toward lower inflammation was visible across all zones in the test group, only the basal zone reached significance. Connective tissue maturation and epithelial regeneration scores were equivalent between groups, suggesting that plasma activation did not accelerate or alter stromal healing in a detectable way. Vascularization was marginally higher in the test group. Strikingly, the cornified epithelial layer in direct contact with the abutment surface was significantly thicker in the plasma-activated group (2.89 ± 0.8 vs. 1.91 ± 0.7, P = 0.008), pointing to enhanced epithelial adaptation at the abutment interface. Clinically, BoP was lower in the test group despite no difference in plaque accumulation, which aligns with the histological picture of a less inflamed sulcular environment.

The clinical relevance of these findings lies in the transmucosal zone. A thicker cornified layer and reduced basal inflammation together suggest that plasma-activated surfaces may promote a more stable, better-sealed epithelial attachment — a biological barrier against sulcular contamination. For the implantologist, this translates into a potentially more resilient soft tissue seal around the abutment, achievable with a simple, chairside surface treatment applied immediately before placement. The effect size is modest and the follow-up limited to three months, but the histological signal is clear and mechanistically plausible. Larger trials with longer observation periods are warranted to determine whether these early tissue-level advantages translate into measurable clinical outcomes over time.